因此,在卵巢癌脑转移或脑膜播散的情况下,无论患者是否携带BRCA突变,均应考虑使用PARPi。 参考文献:Nei T, Tamauchi S, Ikeda Y, Yoshikawa N, Niimi K, Kajiyama H. Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. J Obstet Gynaecol Res...
5.Paul DiSilvestro, et al. Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib i...
参考文献:Nei T, Tamauchi S, Ikeda Y, Yoshikawa N, Niimi K, Kajiyama H. Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. J Obstet Gynaecol Res. 2023 Apr 28. doi: 10.1111/jog.15663. Epub ahead of print. PMID: 37114359.发...
This month, two studies in theJCIinvestigated the mechanisms underlying thetreatment resistanceassociated with some BRCA1 mutations, and the findings provide information that may help predict which treatments will be effective in women with breast andovarian cancer. A team led by Jos Jonkers at the ...
Ovarian cancer patient without BRCA mutation who relapsed 7 months after platinum-based first-line treatment Cancer & Chemotherapy ReviewsAndreetta, Claudia
Therefore, the ability to identify subgroups of pancreatic cancer with unique biological characteristics and treatment response is urgently needed. In addition to breast and ovarian cancer, pancreatic cancer is the third most common cancer type that is related to the early onset (BRCA) gene mutation...
The therapeutic effect of PARPi monotherapy and platinum-based chemotherapy was equivalent for BRCA1/2-mutant ovarian cancer patients with secondary platinum-sensitive recurrence. The prolonged PFI with PARPi monotherapy did ...
treatment cap;No new safety signals were identified; the incidence of MDS/AML remained low and new primary malignancies remained balanced between treatment groups;Results support the use of maintenance olaparib to achieve long-ter...
[6] O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961-967. doi:10.1093/carcin/bgq069 [7] Grinda T, Delaloge S. BRCA2: a 25-year journey from gene identific...
Patients with platinum-resistant/refractory high-grade serous ovarian cancer (HGSOC) with no BRCA mutation have a poor prognosis and limited treatment options. Based on pre-clinical and early clinical studies, it was hypothesi...